CARVYKTI 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/11000
Periodic Safety Update EU Single assessment - 
12/10/2023 
07/12/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202302 
ciltacabtagene autoleucel 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/11000/202302. 
II/0018 
B.II.b.2.b - Change to importer, batch release 
09/11/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
product and any of the test methods at the site is a 
biol/immunol method 
IB/0024 
B.II.g.4.b - Changes to an approved change 
27/10/2023 
n/a 
management protocol - Minor changes that do not 
change the strategy defined in the protocol 
IA/0022 
A.6 - Administrative change - Change in ATC 
25/07/2023 
07/12/2023 
SmPC 
Code/ATC Vet Code 
II/0019 
B.II.b.2.b - Change to importer, batch release 
20/07/2023 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
product and any of the test methods at the site is a 
biol/immunol method 
II/0016 
B.I.b.1.e - Change in the specification parameters 
22/06/2023 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the AS and/or the FP 
IB/0020 
B.I.b.2.e - Change in test procedure for AS or 
19/06/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0015/G 
This was an application for a group of variations. 
28/04/2023 
n/a 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0005 
B.I.b.2.d - Change in test procedure for AS or 
30/03/2023 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0014 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
28/03/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
R/0008 
Renewal of the marketing authorisation. 
26/01/2023 
24/03/2023 
SmPC, Annex 
The CAT/CHMP, having reviewed the available information 
II and PL 
on the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for CARVYKTI, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0010/G 
This was an application for a group of variations. 
17/03/2023 
n/a 
B.I.e.5.c - Implementation of changes foreseen in an 
approved change management protocol - For a 
biological/immunological medicinal product 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
PSUSA/11000
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
ciltacabtagene autoleucel 
N/0013 
Minor change in labelling or package leaflet not 
09/03/2023 
07/12/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0012 
B.I.a.1.f - Change in the manufacturer of AS or of a 
17/02/2023 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0011 
B.I.e.5.c - Implementation of changes foreseen in an 
14/02/2023 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
II/0004/G 
This was an application for a group of variations. 
15/12/2022 
24/03/2023 
SmPC and PL 
SmPC new text: 
Grouped application comprising two type II 
variations as follows: 
Patients who develop HLH may have an increased risk of 
severe bleeding. 
Patients treated with CARVYKTI may be at an increased risk 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of severe/fatal COVID-19 infections. Patients should be 
counselled on the importance of prevention measures. 
For more information, please refer to the Summary of 
Product Characteristics. 
- Update of section 4.4 of the SmPC in order to add a 
new warning on increased risk of severe/fatal 
COVID-19 infections following Covid-19 signal 
evaluation from the ongoing study 
68284528MMY3002 (CARTITUDE-4) based on a 
cumulative review of all clinical trials, registries and 
literature. 
- Update of section 4.4 of the SmPC in order to add a 
new warning Risk of severe bleeding in the context 
of hemophagocytic lymphohistiocytosis syndrome 
(HLH) following a signal evaluation from the ongoing 
study 68284528MMY3002 (CARTITUDE-4) based on 
cumulative review of all clinical trials, registries and 
literature. 
The Package Leaflet is updated accordingly. 
The RMP version 2.2 has also been submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0003 
Update of sections 4.4 and 4.8 of the SmPC in order 
15/12/2022 
24/03/2023 
SmPC, 
For more information, please refer to the Summary of 
to update the existing warnings on cytokine release 
Labelling and 
Product Characteristics. 
syndrome (CRS), neurologic toxicities and grading of 
PL 
related events and to update the list of adverse drug 
reactions (ADRs) based on previously reviewed data 
from studies MMY2001 and MMY2003, and an 
additional internal characterisation of neurotoxicity 
Page 5/6 
 
 
 
 
 
 
 
 
risk; the Package Leaflet is updated accordingly. The 
RMP version 2.1 has also been submitted. In 
addition, the MAH took the opportunity to introduce 
minor editorial changes to the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0007 
B.I.a.2.a - Changes in the manufacturing process of 
24/11/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0006 
B.I.b.1.b - Change in the specification parameters 
10/11/2022 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
II/0002 
B.I.a.2.c - Changes in the manufacturing process of 
10/11/2022 
n/a 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
IB/0001 
B.I.b.2.a - Change in test procedure for AS or 
11/10/2022 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
